MGB Biopharma has exclusive worldwide license rights to the University of Strathclyde’s MGB patent estate for all fields except anti-cancer (non-exclusive).
Patents have been granted in the EU, US and UK, and are pending in India, China, and Japan.
The MGB technology has been licensed from the University of Strathclyde and has so far demonstrated very significant in vitro and in vivo activity against Gram-positive bacteria, including MRSA and also against some Gram-negative bacteria, viral, fungi and parasitic pathogens.
The technology arose from the work of a University of Strathclyde multidisciplinary team, comprising of medicinal chemists, molecular modellers and microbiologists.
The initial development of the technology was created entirely through Scottish-based funding, initially through the former Synergy Fund, owned by the University of Strathclyde and the University of Glasgow, then through Scottish Enterprise‘s Proof of Concept Programme and from royalties from Leucovorin®, the cancer treatment produced from research at the University of Strathclyde in the 1980’s.
University of Strathclyde